Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression

• Published in: Human psychopharmacology Vol. 28; no. 5; pp. 516 - 522
• Main Authors: Ng, Chee, Sarris, Jerome, Singh, Ajeet, Bousman, Chad, Byron, Keith, Peh, Lai Huat, Smith, Deidre Joy, Tan, Chay Hoon, Schweitzer, Isaac
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.09.2013
• Subjects: Adult; Antidepressive Agents, Second-Generation - therapeutic use; Aryl Hydrocarbon Hydroxylases - genetics; Asian Continental Ancestry Group - ethnology; Asian Continental Ancestry Group - genetics; Citalopram - therapeutic use; Cyclohexanols - therapeutic use; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6 - genetics; Depressive Disorder, Major - drug therapy; Depressive Disorder, Major - ethnology; Depressive Disorder, Major - genetics; ethnopsychopharmacology; European Continental Ancestry Group - ethnology; European Continental Ancestry Group - genetics; Female; Humans; Male; Middle Aged; personalized medicine; Pharmacogenetics - methods; pharmacogenomic; Polymorphism, Genetic - genetics; Prospective Studies; Serotonin Plasma Membrane Transport Proteins - genetics; Single-Blind Method; Time Factors; Venlafaxine Hydrochloride; Young Adult; ethnopsychopharmacology; pharmacogenomic; personalized medicine

Objective The objective of this study is to investigate the influence of the 5‐HTTLPR (serotonin transporter‐linked promoter region), cytochrome P450 2C19, and cytochrome P450 2D6 polymorphisms on escitalopram (ESC) and venlafaxine (VEN) responses in major depressive disorder. Method A prospective m...